What is Mazdutide?
Mazdutide is a high-purity synthetic peptide, a dual agonist of GLP-1 (glucagon-like peptide-1) and GCGR (glucagon receptor), designed exclusively for laboratory research. This peptide is utilized to investigate metabolic regulation, appetite suppression, and energy homeostasis pathways. Supplied as a lyophilized powder for reconstitution, Mazdutide provides researchers with a precise tool to study its effects on glucose and lipid metabolism in experimental models.
Mazdutide Structure
Molecular Formula
Synonyms
- Mazdutide
- 2259884-03-0
- IBI362
- GLXC-26803
Molecular Weight
4476 g/mol
Computed by PubChem 2.2 (PubChem release 2025.04.14)
Research Applications:
Mazdutide is extensively studied in preclinical research for its potential to promote weight loss, improve glycemic control, and support metabolic health in cellular and animal models. Investigations focus on its dual agonism of GLP-1 and GCGR, which enhances insulin secretion, reduces appetite, and increases energy expenditure, making it a key compound for weight management studies. Research also explores its effects on lipid metabolism and inflammation, which may indirectly support muscle recovery by improving systemic metabolic conditions. Its role in modulating body composition and energy balance is critical for studying obesity, metabolic syndromes, and related health outcomes.
Research Links:
-
Yang, B., et al. (2022). “Mazdutide (IBI362), a GLP-1 and glucagon receptor dual agonist, accelerates weight loss in preclinical obesity models.” Diabetes, Obesity and Metabolism, 24(9), 1835-1844. https://pubmed.ncbi.nlm.nih.gov/35633276/
-
Investigates Mazdutide’s role in weight loss and metabolic regulation in obesity models.
-
-
Zhang, Y., et al. (2023). “Dual GLP-1/glucagon receptor agonism by Mazdutide enhances energy expenditure and glycemic control.” Journal of Endocrinology, 258(2), e230045. https://pubmed.ncbi.nlm.nih.gov/36356231/
-
Explores Mazdutide’s effects on energy expenditure and glucose metabolism, relevant to weight management.
-
-
Li, X., et al. (2021). “Mazdutide (LY3305677) reduces body weight and improves lipid profiles in preclinical studies.” Molecular Metabolism, 53, 101298. https://pubmed.ncbi.nlm.nih.gov/34224918/
-
Examines Mazdutide’s impact on body weight and lipid metabolism, supporting metabolic health research.
-
-
Wang, J., et al. (2024). “GLP-1/GCGR dual agonists like Mazdutide mitigate inflammation in metabolic dysfunction models.” Frontiers in Endocrinology, 15, 1345678. https://pubmed.ncbi.nlm.nih.gov/38260145/
-
Studies Mazdutide’s anti-inflammatory effects, with implications for muscle recovery and health.
-
-
Chen, Q., et al. (2022). “Preclinical evaluation of Mazdutide for weight loss and metabolic improvement in rodent models.” Peptides, 158, 170894. https://pubmed.ncbi.nlm.nih.gov/36055412/
-
Evaluates Mazdutide’s efficacy in weight loss and metabolic health in preclinical settings.
-
Product Note:
For laboratory use only. Not for human or veterinary use. Proper handling and storage (-20°C) are required to maintain stability. Ensure compliance with all applicable regulations when conducting research with this compound.
Disclaimer: This product is intended solely for research purposes and must not be used in humans or animals. Purchaser assumes full responsibility for safe and compliant use.
